AXSOME THERAPEUTICS INC (AXSM) Stock News
NASDAQ:AXSM - Nasdaq - US05464T1043 - Common Stock - Currency: USD
AXSM Latest News, Press Relases and Analysis
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
Is Intel Corp Stock a Buy?
Intel stock has sharply lagged its sector, slumping 32% over the past year. The past few years have been difficult -- to say the least -- for Intel (NASDAQ: INTC). Competitors like Nvidia have seen their share prices balloon thanks to the rapid rise of AI technologies.
SolarEdge upgraded to Market Perform from Underperform at Northland
Northland upgraded SolarEdge (SEDG) to Market Perform from Underperform with an unchanged price target of $15.50. Shares have declined meaningfully since the firm’s downgrade on May 16, notes the analyst, who argues that regardless of what legislation ultimately looks like, utility-scale solar is “the cheapest and fastest way to add generation capacity” and SolarEdge is well-positioned as a non-Chinese supplier with cybersecurity capabilities. Published first on TheFly – the ultimate source for
3 Reasons to Buy This Artificial Intelligence (AI) Stock Like There Is No Tomorrow
Meta Platforms has a vast ecosystem to monetize in the AI race. The company is investing heavily in AI-related infrastructure. Artificial intelligence (AI) isn't new, but novel applications of the technology have become extremely popular in the past few years.
3 High-Flying Stocks That Could Soar Even More
Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit Therapeutics could keep its momentum going with positive clinical results for cancer drug ivonescimab. Here's why they picked Alnylam Pharmaceuticals (NASDAQ: ALNY), Axsome Therapeutics (NASDAQ: AXSM), and Summit Therapeutics (NASDAQ: SMMT).
Target Stock: Time to Panic?
Target missed estimates and cut its guidance in its first-quarter earnings report. Target (NYSE: TGT) has been one of the most disappointing retail stocks on the market recently. After another earnings report came in well below both analysts' and the company's expectations, Target seems as far away from a recovery as ever.
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them?
The Trade Desk stock tumbled earlier this year, but its first-quarter results sent the stock sharply higher. For investors that still have many years before retirement, growth stocks are one of the most efficient ways to increase their net worth.
3 Monster Stocks in the Making
Axsome Therapeutics is taking off, led by a treatment for major depressive disorder. Iovance Biotherapeutics could transform how solid tumors are treated. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance Biotherapeutics (NASDAQ: IOVA), and Viking Therapeutics (NASDAQ: VKTX) are monster stocks in the making.
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million,...
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: TGTX
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ALNY
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
I'm in my 30s and just got married. I want to sell my home, move in with my spouse. Is selling the best move?
There are many things to consider when selling a home. Here's how to navigate them.
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc....